Literature DB >> 10147049

Medicaid drug utilisation review under OBRA 1990: current issues and future directions.

T R Fulda1, S L Hass.   

Abstract

Mesh：

Year:  1992        PMID： 10147049     DOI： 10.2165/00019053-199202050-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  3 in total

Review 1.  Experience of state drug benefit programs.

Authors:  S B Soumerai; D Ross-Degnan
Journal:  Health Aff (Millwood)       Date:  1990       Impact factor: 6.301

2.  Incompatible goals. Experience with the Medicaid program offers lessons about the economics and politics of public-sector health insurance.

Authors:  C H Nye
Journal:  Health Manage Q       Date:  1991

3.  Savings for Medicaid drug spending.

Authors:  M R Pollard; J M Coster
Journal:  Health Aff (Millwood)       Date:  1991       Impact factor: 6.301
  3 in total
  5 in total

Review 1.  Economic impact of cost-containment strategies in third party programmes in the US. Part II.

Authors:  C M Kozma; R M Schulz; W M Dickson; J T Dye; E R Cox; D A Holdford; L Michael; W N Yates; T L Young
Journal:  Pharmacoeconomics       Date:  1993-09       Impact factor: 4.981

2.  Regulation of pharmaceutical prices: a managed care perspective.

Authors:  R P Navarro
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

Review 3.  Impact of drug usage review on drug utilisation.

Authors:  J L Blackburn
Journal:  Pharmacoeconomics       Date:  1993-01       Impact factor: 4.981

4.  Strategic use of pharmacoeconomic research in early drug development and global pricing.

Authors:  K Clemens; L P Garrison; A Jones; F Macdonald
Journal:  Pharmacoeconomics       Date:  1993-11       Impact factor: 4.981

Review 5.  Cephalosporin utilisation review and evaluation.

Authors:  G M Misan; C Dollman; D R Shaw; N Burgess
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.